Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Slides:



Advertisements
Similar presentations
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
Advertisements

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Tetsuro Tsujimoto, Hiroshi Kajio  International Journal of Cardiology 
Stephen W. Waldo et al. JACC 2008;51:
Clyde W. Yancy et al. JACC 2017;70:
Noriko Kikuchi et al. JACEP 2016;2:
Nat. Rev. Cardiol. doi: /nrcardio
Robert W. Yeh et al. JACC 2017;70:
Nat. Rev. Cardiol. doi: /nrcardio
Patrizio Lancellotti et al. JIMG 2016;9:
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Shadi Al Halabi et al. JACEP 2015;1:
Nat. Rev. Cardiol. doi: /nrcardio
Dean J. Kereiakes et al. JACC 2017;70:
G. Michael Felker et al. JCHF 2014;2:
Kenshi Hayashi et al. JACEP 2016;2:
Alan G. Japp et al. JACC 2016;67: Differentiation of Athlete’s Heart From Early DCM by Myocardial Deformation Imaging Two-dimensional speckle.
Johannes Steiner et al. JACC 2017;70:
Johannes Steiner et al. JACC 2017;70:
Belinda Gray et al. JCHF 2013;1:
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Johannes Steiner et al. JACC 2017;70:
Tetsuro Tsujimoto, Hiroshi Kajio  International Journal of Cardiology 
Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis  C.A. Rushton,
Wayne L. Miller et al. JCHF 2013;1:
Mohit K. Turagam et al. JACEP 2017;3:
Khurram Nasir et al. JACC 2015;66:
K.R. Julian Chun et al. JACEP 2017;3:
Jordan B. King et al. JCHF 2016;4:
G. Michael Felker et al. JCHF 2014;2:
Svend A. Mortensen et al. JCHF 2014;2:
Nicolaj C. Hansson et al. JACC 2016;68:
Kenshi Hayashi et al. JACEP 2016;2:
Connie W. Tsao et al. JCHF 2016;4:
Shahrokh Javaheri et al. JACC 2017;69:
Peter E. Carson et al. JCHF 2015;3:
Pamela E. Scott et al. JACC 2018;71:
Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.
Emilce Trucco et al. JACEP 2018;j.jacep
Rami Doukky et al. JCHF 2016;4:24-35
Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.
Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.
Maria Rosa Costanzo et al. JCHF 2016;4:95-105
Michael V. McConnell et al. JACC 2018;71:
Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,
Jeffrey L. Anderson et al. JACC 2007;50:e1-e157
Glenn N. Levine et al. JACC 2011;58:e44-e122
Jordan B. King et al. JCHF 2016;4:
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Davide Capodanno et al. JCIN 2009;2:
Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.
Connie W. Tsao et al. JCHF 2016;4:
Rick A. Nishimura et al. JACC 2019;73:
Saadia Sherazi et al. JACEP 2015;1:74-80
EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.
Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.
Lifetime heart failure risk*
Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.
Rick A. Nishimura et al. JACC 2017;70:
Dennis M. McNamara et al. JCHF 2014;2:
Jeffrey Senfield et al. JACEP 2017;3:
Orly Vardeny et al. JCHF 2016;4:
Evan M. Zahn et al. JCIN 2016;9: Relationship Between Patent Ductus Arteriosus Closure and Left Ventricular Ejection Fraction The graph depicts.
Gianluigi Savarese et al. JCHF 2016;4:
One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.
Patient selection process in the present study.
Constantijn Franssen et al. JCHF 2016;4:
Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.
Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.
Presentation transcript:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:1489-1496 An Example of Clinically Important Subclassification of Phenotypes Three distinct subgroups developed through phenomapping of detailed clinical data in 397 patients with a diagnosis of heart failure (HF) with preserved ejection fraction. After adjustment for known risk factors, a patient’s subgroup was significantly associated with adverse outcomes. Data are from Shah et al. (17). CV = cardiovascular. Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:1489-1496 American College of Cardiology Foundation